Anti Vegf Eylea Hd denied as not medically necessary by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Eylea HD (aflibercept) on Medical-Necessity Grounds

Humana's medical-necessity denials for Eylea HD (high-dose aflibercept) almost always trace to one of three documentation gaps: insufficient evidence of an active, qualifying retinal diagnosis; a chart that does not clearly show prior treatment history and clinical response; or a prescriber's request that does not map the patient's specific findings to the criteria in Humana's published coverage policy. Because retinal conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and related disorders are time-sensitive, these denials are worth fighting promptly.

## Why This Denial Is Appealable

FDA approval of Eylea HD is well established for specific retinal indications, and the applicable retinal-disease guidelines from recognized bodies such as the American Academy of Ophthalmology support anti-VEGF therapy as a standard of care. A denial that contradicts your ophthalmologist's documented clinical judgment and the drug's FDA-approved labeling can be challenged on both clinical and procedural grounds.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you are entitled to a full-and-fair internal review. Submit within the timeframe shown on your denial letter (typically 180 days).
• External review: If the internal appeal fails, you may request an independent external review through an accredited Independent Review Organization (IRO). The external-review window is generally within four months of a final internal denial.
• Expedited review: Because retinal conditions can cause irreversible vision loss if treatment is delayed, request an expedited (72-hour) review at the same time you file internally. Document why delay would cause serious harm.

## Concrete Appeal Steps and Timeline

1. Request the complete denial letter and Humana's medical/coverage policy for aflibercept — both are available on request. 2. Have your ophthalmologist prepare a detailed medical-necessity letter within 5–7 business days. 3. Submit the internal appeal package to the address or portal shown on the denial notice. 4. Request expedited track in writing, citing potential for irreversible vision loss. 5. If denied again, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Retinal imaging (OCT, fluorescein angiography), visual-acuity measurements, and clinic notes confirming the specific qualifying diagnosis.
• Prior-treatment history: Dates, drug names, doses (from the chart), and documented outcomes for any anti-VEGF or other therapies already tried.
• Clinical severity: Chart language describing lesion activity, fluid presence, visual-acuity trajectory, and the treating physician's assessment of urgency.
• Prescriber medical-necessity letter: Should state the diagnosis, why Eylea HD is medically necessary, how the patient meets the criteria in the FDA-approved prescribing label, and why alternatives are inadequate for this patient.

## Criteria-Mapping Structure

Copy every requirement from (a) the Eylea HD FDA-approved prescribing information and (b) Humana's current published coverage policy for aflibercept. For each criterion, write the exact supporting fact from the patient's chart — date of finding, value recorded, and the clinician who documented it. This one-to-one map is the single most persuasive element of any medical-necessity appeal.